The locus coeruleus (LC) is involved in several neural pathways responsible for some somatic and emotional processes, such as pain and depression; its activity is regulated by several receptors, such as opioid, ␣ 2 -adrenergic, and 5-hydroxytryptamine (5-HT) 1A receptors. The present study investigates the in vivo effects of venlafaxine, an antidepressant with analgesic properties, on locus coeruleus neurons, and its modulation by opioid, ␣ 2 -adrenergic, and 5-HT 1A receptors. The results show that acute administration of venlafaxine produced a dose-dependent, complete inhibition of LC activity. This inhibitory effect was not reversed by the opioid receptor antagonist naloxone, but subsequent administration of idazoxan, an ␣ 2 -adrenoceptor antagonist, did reverse it. The preadministration of the 5-HT 1A receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 g/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED 50 by 56 and 44%, respectively. A 14-day treatment with venlafaxine (40 mg/kg/ day) induced a suppression of the firing activity of LC neurons. In these treated animals, venlafaxine produced an inhibitory effect similar to that in nontreated animals. This inhibitory effect was not reversed by naloxone, but it was reversed by idazoxan. In addition, the preadministration of 8-OH-DPAT (40 g/kg) significantly enhanced the venlafaxine effect, decreasing the ED 50 by 60%. These results suggest that the effect of venlafaxine on LC neurons is modulated by ␣ 2 -adrenergic and 5-HT 1A receptors, and not by opioid receptors. These data could contribute to the further understanding of the antidepressant and analgesic mechanism of action of venlafaxine.Venlafaxine is a dual 5-hydroxytryptamine (serotonin)/ noradrenaline (5-HT/NA) reuptake inhibitor (SNRI) antidepressant that blocks the synaptosomal uptake of 5-HT at low doses and NA at higher doses (Muth et al., 1986;Dawson et al., 1999). In addition to its antidepressant effect, venlafaxine also has analgesic properties (Saarto and Wiffen, 2005). The fact that antidepressants have antidepressant and analgesic properties suggests that monoamines, and primarily 5-HT and NA, are implicated in depression as well as in pain. These pathologies have a high comorbidity, implying a possible interrelated or common neurochemical mechanism and/or neuroanatomical substrate.